The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Lenalidomide and azacitidine with radiotherapy for patients with plasmacytomas
Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the design of a single center study (NCT04174196) of oral azacitidine, lenalidomide and radiotherapy in newly diagnosed solitary plasmacytoma of the bone (SPB) or relapsed multiple myeloma with plasmacytomas amenable to radiotherapy. There is a 60% chance of progression to multiple myeloma over 3 years in SPB patients with minimal bone marrow involvement. Despite this risk, there are no approved therapies for this setting, and localized radiation is the standard of care. Previous studies have demonstrated the synergistic action of lenalidomide plus azacitidine, through cancer testis antigen (CTA) upregulation, and enhancement of CTA-specific immune responses. It is hypothesized that adding this combination to radiotherapy may lead to clinically beneficial immune-mediated effects against plasmacytomas. The study will primarily assess efficacy, with safety and survival outcomes serving as secondary endpoints. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consulting: GenMab, Amgen, Boehringer Ingelheim, Janssen, Bristol-Myers Squibb
Research funding: Genentech, Pfizer, Janssen, Bristol-Myers Squibb
Patent: Serametrix
